Physician profile
Cody Rogers
NPI 1437714474
$3,184.61
in general payments reported to CMS, 2019-2025
31 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $822 · 2024: $1,219 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $539.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $523.33 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $355.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $258.03 | 2022-2025 | Vraylar |
| Exact Sciences Corporation | $181.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $144.42 | 2025 | |
| Amgen INC. | $104.23 | 2024-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $92.37 | 2023-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $85.39 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $81.35 | 2022-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $80.89 | 2023-2024 | |
| Glaxosmithkline, LLC. | $76.28 | 2023-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $74.69 | 2024-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $66.03 | 2023-2024 | Veozah |
| Shield Therapeutics INC | $63.89 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.28 | 2022-2024 | Jardiance |
| Dexcom, INC. | $58.70 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $38.71 | 2022-2025 | Korlym |
| Merck Sharp & Dohme LLC | $34.43 | 2023 | Verquvo, Belsomra, Varivax |
| Mayne Pharma Commercial LLC | $30.43 | 2023 | |
| Acadia Pharmaceuticals INC | $27.30 | 2024 | Daybue |
| Medtronic, INC. | $26.90 | 2022-2024 | Minimed 780g |
| Lucid Diagnostics INC. | $26.04 | 2022 | |
| Inspire Medical Systems, INC. | $25.17 | 2023 | Inspire |
| Otsuka America Pharmaceutical, INC. | $23.84 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $21.76 | 2023 | Jornay Pm |
| Alnylam Pharmaceuticals INC. | $18.92 | 2023 | Amvuttra |
| Antares Pharma, INC. | $18.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.26 | 2022 | |
| Boston Scientific Corporation | $14.51 | 2025 | General - Pain Management |
| Linus Health, INC. | $14.18 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.